Literature DB >> 17385941

Optimal management strategies for chronic iron overload.

James C Barton1.   

Abstract

Iron overload is characterised by excessive iron deposition and consequent injury and dysfunction of target organs, especially the heart, liver, anterior pituitary, pancreas and joints. Iron overload disorders are common worldwide and occur in most major race/ethnicity groups. Physiological mechanisms to excrete iron are very limited. Thus, all patients with iron overload need safe and effective treatment that is compatible with their co-existing medical conditions. Treatments for iron overload include phlebotomy and erythrocytapheresis that remove iron predominantly as haemoglobin, and chelation therapy with drugs that bind excess iron selectively and increase its excretion. The most important potential benefits of therapy are preventing deaths due to cardiac siderosis and hepatic cirrhosis. Preventing iron-related injury to endocrine organs is critical in children. Successful treatment or prevention of iron overload increases quality of life and survival in many patients. This article characterises the major categories of iron overload disorders, tabulates methods to evaluate and treat iron overload, and describes treatment options for iron overload disorders. Research needed to advance knowledge about treatment of iron overload is proposed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17385941     DOI: 10.2165/00003495-200767050-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  143 in total

Review 1.  Secondary iron overload.

Authors:  J P Kushner; J P Porter; N F Olivieri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2001

2.  Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome.

Authors:  P D Jensen; I M Jensen; J Ellegaard
Journal:  Br J Haematol       Date:  1992-01       Impact factor: 6.998

3.  Myelodysplastic syndromes clinical practice guidelines in oncology.

Authors:  Peter L Greenberg; Maria R Baer; John M Bennett; Clara D Bloomfield; Carlos M De Castro; H Joachim Deeg; Marcel P Devetten; Peter D Emanuel; Harry P Erba; Eli Estey; James Foran; Steven D Gore; Michael Millenson; Willlis H Navarro; Stephen D Nimer; Margaret R O'Donnell; Hussain I Saba; Kathy Spiers; Richard M Stone; Martin S Tallman
Journal:  J Natl Compr Canc Netw       Date:  2006-01       Impact factor: 11.908

4.  Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.

Authors:  Annita Kolnagou; George J Kontoghiorghes
Journal:  Hemoglobin       Date:  2006       Impact factor: 0.849

Review 5.  Preclinical and clinical development of deferitrin, a novel, orally available iron chelator.

Authors:  Joanne M Donovan; Melissa Plone; Rafif Dagher; Mark Bree; Judith Marquis
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

6.  Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis.

Authors:  Ellen Butensky; Roland Fischer; Mark Hudes; Laurie Schumacher; Roger Williams; Thomas P Moyer; Elliott Vichinsky; Paul Harmatz
Journal:  Am J Clin Pathol       Date:  2005-01       Impact factor: 2.493

7.  Erythrocytapheresis with recombinant human erythropoietin in hereditary hemochromatosis therapy: a new alternative.

Authors:  A Kohan; R Niborski; J Daruich; J Rey; F Bastos; G Amerise; R Herrera; M García; W Olivera; M T Santarelli; J S Avalos; J Findor
Journal:  Vox Sang       Date:  2000       Impact factor: 2.144

8.  High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation.

Authors:  M A Aldouri; B Wonke; A V Hoffbrand; D M Flynn; S E Ward; J E Agnew; A J Hilson
Journal:  Acta Haematol       Date:  1990       Impact factor: 2.195

9.  Iron-chelation therapy with oral deferiprone in patients with thalassemia major.

Authors:  N F Olivieri; G M Brittenham; D Matsui; M Berkovitch; L M Blendis; R G Cameron; R A McClelland; P P Liu; D M Templeton; G Koren
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

10.  Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo.

Authors:  O Shalev; T Repka; A Goldfarb; L Grinberg; A Abrahamov; N F Olivieri; E A Rachmilewitz; R P Hebbel
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

View more
  4 in total

Review 1.  Synthetic and natural iron chelators: therapeutic potential and clinical use.

Authors:  Heather C Hatcher; Ravi N Singh; Frank M Torti; Suzy V Torti
Journal:  Future Med Chem       Date:  2009-12       Impact factor: 3.808

Review 2.  Ferritin for the clinician.

Authors:  Mary Ann Knovich; Jonathan A Storey; Lan G Coffman; Suzy V Torti; Frank M Torti
Journal:  Blood Rev       Date:  2008-10-02       Impact factor: 8.250

Review 3.  Deferasirox : a review of its use in the management of transfusional chronic iron overload.

Authors:  Lily P H Yang; Susan J Keam; Gillian M Keating
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Glycoside rich fraction from Spondias pinnata bark ameliorate iron overload induced oxidative stress and hepatic damage in Swiss albino mice.

Authors:  Dipankar Chaudhuri; Nikhil Baban Ghate; Sourav Panja; Tapasree Basu; Anil Khushalrao Shendge; Nripendranath Mandal
Journal:  BMC Complement Altern Med       Date:  2016-07-29       Impact factor: 3.659

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.